Contrast developer Guerbet reported a drop in revenues for 2020 due to the ongoing COVID-19 pandemic.
For the full fiscal year (end-December 31), the firm posted revenue of 712.3 million euros ($862.9 million U.S.) at current exchange rates, down 12.8% compared with revenue of 816.9 million euros ($989.6 million) in 2019. However, at constant exchange rates, Guerbet's revenue was down 10% at 735.4 million euros ($890.8 million).
For diagnostic imaging in particular, revenue totaled 637.2 million euros ($771.9 million U.S.), down 11.4% at constant exchange rates, compared with 719.4 million euros ($871.5 million U.S.) in 2019.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
